Our Reference: IND 23522

ADVICE
September 21, 2021

AstraZeneca Pharmaceuticals LP
Attention: Elizabeth Daglish
One MedImmune Way
Gaithersburg, MD 20878

Dear Ms. Daglish

Please refer to your Investigational New Drug Application (IND) 23522 submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act for AZD1222, "Human Coronavirus, Recombinant (Chimpanzee Adenovirus Vector Expressing SARS-CoV-2 Spike Protein; Human Cytomegalovirus Promoter; Replication Defective; E1 and E3 gene deletion, T-Rex-293 Cells) Vaccine," for the prevention of COVID-19 disease.

Please also refer to your amendments submitted to your IND
submitted and received on August 20, 2021; and
submitted and received on September 13, 2021.

In our letter dated August 6, 2021, we informed you that we determined that although the Emergent Manufacturing Operations Baltimore, LLC (EMOB) Bayview facility was not operating in substantial conformity with Current Good Manufacturing Practice requirements during the relevant time period, the drug substance (DS) lots 21002248, 21002635, and 21002636 were acceptable for use, considering the current COVID-19 public health emergency. We also noted that although the export of these lots did not fit within any of the applicable exemptions for the export of an unapproved biological product under the Food, Drug, and Cosmetic (FD&C) Act, FDA did not intend to object to the export of DS lots 21002248, 21002635, and 21002636, or product made from these lots provided that certain conditions were met.

Subsequently, you informed the Agency that EMOB identified additional deviations that are linked to these lots. Based on our review of the available data and information for AstraZeneca's ChAdOx1 nCOV19 vaccine DS lots 21002248, 21002635, and 21002636, these deviations should not negatively impact the quality or safety of the DS. Therefore, our initial assessment of lots 21002635, 21002636, and 21002248 remains that the 21002248, 21002635, and 21002636 lots are acceptable for use, considering the current COVID-19 public health emergency.

We again note that although the export of these lots does not fit within any of the applicable exemptions for the export of an unapproved biological product under the FD&C Act, FDA does not intend to object to the export of DS lots 21002248, 21002635, and 21002636, or product made from these lots provided that the agreed upon Information sheet is included with each pallet of AstraZeneca's ChAdOx1 nCOV19 vaccine that is exported in sufficient quantities to provide one copy per carton, instructions regarding the information sheet are included for those who receive the shipments, and you agree that an unredacted version of the September 21, 2021 addendum to the August 6, 2021 memo *Disposition of AstraZeneca (AZ) AZD1222 Drug Substance (DS) Lots 21002248, 21002635, and 21002636* can be posted on FDA's website. This statement only refers to the above listed lots, and does not refer to any other lots manufactured at this facility nor does it cover vaccine manufactured by combining these lots with different lots of drug substance.

FDA expects that all records and deviations associated with the manufacture of AZD1222 DS at EMOB have been reviewed by AstraZeneca and reported to the Agency. Additionally, it is the Agency's expectation that any deviation discovered to be associated with DS lots 21002248, 21002635, and 21002636, including untimely reported deviations, will be reported to FDA expeditiously and to any relevant foreign regulatory authority, including those foreign regulatory authorities who have been in receipt or will be in receipt of product from these lots. AstraZeneca is expected to cease export until such time as the Agency has reviewed the information provided and has made a determination on the AZD1222 DS lots. In the event the export has occurred or begun on certain lots, it is the Agency's expectation that AstraZeneca will notify the relevant foreign authority regarding any additional deviation and provide the foreign authority with full documentation regarding the additional deviation. FDA expects AstraZeneca to be in open and regular communication with the relevant foreign authority and to implement a process to proactively provide such information promptly.

If you have any questions, please contact the Regulatory Project Manager, Laura Montague at 240-204-4519 or Laura.Montague@fda.hhs.gov

Sincerely,

Marion Gruber, PhD
Director
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research